These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21203899)

  • 21. ESPL1 is a candidate oncogene of luminal B breast cancers.
    Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
    Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Loi S
    Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.
    Coutant C; Rouzier R; Qi Y; Lehmann-Che J; Bianchini G; Iwamoto T; Hortobagyi GN; Symmans WF; Uzan S; Andre F; de Thé H; Pusztai L
    Clin Cancer Res; 2011 Apr; 17(8):2591-601. PubMed ID: 21248301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
    Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
    Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.
    Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
    Breast Cancer Res Treat; 2011 Feb; 126(1):93-9. PubMed ID: 21184268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    Oh DS; Troester MA; Usary J; Hu Z; He X; Fan C; Wu J; Carey LA; Perou CM
    J Clin Oncol; 2006 Apr; 24(11):1656-64. PubMed ID: 16505416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXA1 is an independent prognostic marker for ER-positive breast cancer.
    Mehta RJ; Jain RK; Leung S; Choo J; Nielsen T; Huntsman D; Nakshatri H; Badve S
    Breast Cancer Res Treat; 2012 Feb; 131(3):881-90. PubMed ID: 21503684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.
    Yamashita H; Toyama T; Nishio M; Ando Y; Hamaguchi M; Zhang Z; Kobayashi S; Fujii Y; Iwase H
    Breast Cancer Res; 2006; 8(4):R48. PubMed ID: 16869955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
    Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
    Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COX2 overexpression is a prognostic marker for Stage III breast cancer.
    Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
    Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.
    Mook S; Knauer M; Bueno-de-Mesquita JM; Retel VP; Wesseling J; Linn SC; Van't Veer LJ; Rutgers EJ
    Ann Surg Oncol; 2010 May; 17(5):1406-13. PubMed ID: 20094918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Total Survivin and acetylated Survivin correlate with distinct molecular subtypes of breast cancer.
    Yakirevich E; Samkari A; Holloway MP; Lu S; Singh K; Yu J; Fenton MA; Altura RA
    Hum Pathol; 2012 Jun; 43(6):865-73. PubMed ID: 22055399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
    Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
    Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular classification of estrogen receptor-positive/luminal breast cancers.
    Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
    Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.
    Mustać E; Zamolo G; Petković M; Dordević G; Radić J; Grgurević E; Batinac T
    Coll Antropol; 2008 Sep; 32(3):741-6. PubMed ID: 18982746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.